| 范文华,吴建华,胡玥,包娜娜,陈华峰,师悦.达格列净联合利拉鲁肽在新诊断超重或肥胖2型糖尿病患者中的应用[J].中国临床保健杂志,2023,26(4):511-514. |
| 达格列净联合利拉鲁肽在新诊断超重或肥胖2型糖尿病患者中的应用 |
| Clinical application of dapagliflozin combined with liraglutide in newly diagnosed overweight/obese type 2 diabetes patients |
| 投稿时间：2023-05-26 |
| DOI：10.3969/J.issn.1672-6790.2023.04.017 |
| 中文关键词: 糖尿病,2型 超重 肥胖症 达格列净 利拉鲁肽 |
| 英文关键词: Diabetes mellitus,type 2 Overweight Obesity Dapagliflozin Liraglutide 〖FL |
| 基金项目: |
|
| 摘要点击次数: 313 |
| 全文下载次数: 855 |
| 中文摘要: |
| 目的 探讨达格列净联合利拉鲁肽对新诊断肥胖2型糖尿病患者糖脂代谢及体重的影响。方法 选取2021年1月1日至2022年12月31日在某干休所就诊的肥胖2型糖尿病(T2DM)患者164例,按照随机数字表法将患者分为2组:达格列净联合利拉鲁肽组(观察组,78例)及基础-餐时胰岛素组(对照组,76例),共观察12周。收集所有患者一般资料,并计算体重指数(BMI)、腰臀比(WHR),治疗前及治疗后分别采集晨血检测空腹血糖(FBG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、胆固醇(TC)等指标,另抽血测餐后2 h血糖(P2hBG)。结果 治疗前,2组之间FBG、P2hBG、BMI、WHR、TG及TC等指标之间均差异无统计学意义。治疗后2组FBG、P2hBG、HbA1c均较治疗前下降,差异均有统计学意义(P值均<0.01)。观察组治疗后TG、TC、BMI、WHR、收缩压(SBP)、舒张压(DBP)均较治疗前下降,差异有统计学意义(P值均<0.05),且组间差异有统计学意义(P值均<0.05)。治疗12周末,观察组无低血糖事件发生,对照组有4例(5%)发生10次轻度低血糖事件。观察组3例(3.6%)发生泌尿系感染,对照组无泌尿系感染事件发生；观察组共有6例(7.1%)出现胃肠道反应,对照组均无胃肠道反应。结论 对新诊断的肥胖T2DM患者,达格列净联合利拉鲁肽治疗的疗效与基础-餐时胰岛素强化治疗疗效相似,同时还具有减轻体重、调脂、降低血压、减少低血糖风险的优势。 |
| 英文摘要: |
| Objective To investigate the effects of dapagliflozin combined with liraglutide on glucose and lipid metabolism and body weight in newly diagnosed overweight or obese patients with type 2 diabetes.Methods One hundred and sixty-four obese type 2 diabetes (T2DM) patients who visited a cadre rest center from January 1,2021 to December 31,2022 were divided into two groups according to random number table:dapagliflozin combined with liraglutide group (observation group,n=84) and basic-meal insulin group (control group,n=80) with a total of 12 weeks of observation.General information from all patients was collected and body mass index (BMI),waist hip ratio (WHR) were calculated,fasting blood glucose (FBG),2-hour postprandial blood glucose (P2hBG),glycated hemoglobin A1c (HbA1c),triglycerides (TG),and cholesterol (TC) were tested.Results Before treatment,there were no significant differences in FBG,P2hBG,BMI,WHR,TG,and TC between the two groups.After treatment,FBG,P2hBG,and HbA1c were all significantly decreased in both groups when compared with before treatment (P<0.01).After treatment,TG,TC,BMI,WHR,systolic blood pressure (SBP),and diastolic blood pressure (DBP) (P<0.05) were all significantly decreased in the observation group when compared with before treatment,and the differences between two groups were statistically significant (P<0.05).After 12 weeks of treatment,there were no hypoglycemic events in the observation group,while 4 cases (5%) had 10 mild hypoglycemic events in control group.3 cases (3.6%) developed urinary tract infections in observation group,while no urinary tract infections occurred in control group.A total of 6 cases (7.1%) experienced gastrointestinal reactions in observation group,while no gastrointestinal reactions were observed in control group.Conclusions The efficacy of dapagliflozin combined with liraglutide treatment is similar to that of basal-meal insulin intensive therapy in newly diagnosed overweight or obese T2DM patients,which has many advantages in reducing weight,adjusting fat,lowering blood pressure,and reducing the risk of hypoglycemia. |
|
查看全文
|
| 关闭 |
|
|
|